Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients
Rosemary Barnes, Stephanie Earnshaw, Raoul Herbrecht, Orla Morrissey, Monica Slavin, Eric Bow, Cheryl McDade, Claudie Charbonneau, David Weinstein, Michal Kantecki, Haran Schlamm, Johan Maertens
Clinical Therapeutics | ELSEVIER | Published : 2015
This work was supported by Pfizer Inc. Dr. Earnshaw and Ms. McDade are employees of RTI Health Solutions and were paid consultants to Pfizer Inc in connection with the development of the decision-analytic model and the manuscript. Editorial support for the manuscript was provided by Jane Bryant and Karen Irving of Complete Medical Communications and was funded by Pfizer Inc. Dr. Schlamm is no longer employed by Pfizer Inc.